These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Xia G; Truitt RL; Johnson BD Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723 [TBL] [Abstract][Full Text] [Related]
3. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease. Chang YJ; Zhao XY; Huang XJ Front Immunol; 2018; 9():3041. PubMed ID: 30619371 [TBL] [Abstract][Full Text] [Related]
4. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Fowler DH; Gress RE Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730 [TBL] [Abstract][Full Text] [Related]
8. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958 [TBL] [Abstract][Full Text] [Related]
9. Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Li JM; Giver CR; Lu Y; Hossain MS; Akhtari M; Waller EK Immunotherapy; 2009 Jul; 1(4):599-621. PubMed ID: 20191089 [TBL] [Abstract][Full Text] [Related]
10. How important is NK alloreactivity and KIR in allogeneic transplantation? Shaffer BC; Hsu KC Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259 [TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy. Talmadge JE Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168 [TBL] [Abstract][Full Text] [Related]
12. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model. Lu YF; Gavrilescu LC; Betancur M; Lazarides K; Klingemann H; Van Etten RA Blood; 2012 Jan; 119(1):273-84. PubMed ID: 22072555 [TBL] [Abstract][Full Text] [Related]
13. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Jones SC; Murphy GF; Korngold R Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217 [TBL] [Abstract][Full Text] [Related]
14. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach. Sinkovics JG Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421 [TBL] [Abstract][Full Text] [Related]
15. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects. Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558 [TBL] [Abstract][Full Text] [Related]
16. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond. Tsirigotis P; Shimoni A; Nagler A Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385 [TBL] [Abstract][Full Text] [Related]
18. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Zheng H; Matte-Martone C; Li H; Anderson BE; Venketesan S; Sheng Tan H; Jain D; McNiff J; Shlomchik WD Blood; 2008 Feb; 111(4):2476-84. PubMed ID: 18045967 [TBL] [Abstract][Full Text] [Related]
19. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia. Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532 [TBL] [Abstract][Full Text] [Related]
20. Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras. Ghosh A; Koestner W; Hapke M; Schlaphoff V; Länger F; Baumann R; Koenecke C; Cornberg M; Welte K; Blazar BR; Sauer MG Blood; 2009 Apr; 113(18):4440-8. PubMed ID: 19182207 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]